Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.
Summary
The companys flagship product, Serranator\xae, helps improve angioplasty procedures by providing more predictable and controlled lumen gain with minimal dissection, while mitigating vessel recoil. "We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease," said Ryan Kaeding, Managing Director, Life Sciences at Trinity Capital. Were confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption," said Brian Walsh, Chairman and CEO of Cagent Vascular. "Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio.